7 Articles On #Esbriet

Marta Ribeiro avatar

by Marta Ribeiro |

Share this article:

Share article via email

1. Genentech’s PF Drug Esbriet Shown To Lower Mortality Rates in New Study

 

<span class="entry-title">Genentech’s PF Drug Esbriet Shown To Lower Mortality Rates in New Study</span><span class="entry-subtitle">FDA-approved oral drug reduced all-cause and disease-related mortality in IPF patients</span>

Read the article here: http://bit.ly/1URSd1G

2. Esbriet’s Promise and Potential as a PF Therapy

 

<span class="entry-title">Esbriet’s Promise and Potential as a PF Therapy</span><span class="entry-subtitle">In exclusive interview, a lead investigator and a Genentech VP discuss drug's efficacy and future development plans</span>

Read the article here: http://bit.ly/1kub6MJ

3. Phase III Trials Reveal That IPF Patients Treated Continually with ESBRIET for Long-term Have Reduced Risk of Death

 

Phase III Trials Reveal That IPF Patients Treated Continually with ESBRIET for Long-term Have Reduced Risk of Death

Read the article here: http://bit.ly/1NuJban

4. ESBRIET Recommended By The American Thoracic Society for IPF Treatment

 

ESBRIET Recommended By The American Thoracic Society for IPF Treatment

Read the article here: http://bit.ly/1Ote9N0

5. Pirfenidone (Esbriet) Shown Efficacious and Safe in Multiple Studies For IPF

 

Pirfenidone (Esbriet) Shown Efficacious and Safe in Multiple Studies For IPF

Read the article here: http://bit.ly/1N9BIZj

6. ESBRIET Found To Be Safe in Patients with Interstitial Lung Disease Associated With Systemic Sclerosis

 

ESBRIET Found To Be Safe in Patients with Interstitial Lung Disease Associated With Systemic Sclerosis

Read the article here: http://bit.ly/1RHdFsS

7. New Data on Genentech’s Esbriet for Idiopathic Pulmonary Fibrosis Presented at 2015 ATS Conference

 

New Data on Genentech’s Esbriet for Idiopathic Pulmonary Fibrosis Presented at 2015 ATS Conference

Read the article here: http://bit.ly/1OWzE8w